Theradiag Announces the Adoption of All Ordinary Resolutions at the Shareholders’ Meeting of May 6, 2021
10 Maggio 2021 - 5:45PM
Business Wire
The Extraordinary Shareholders’ Meeting will be
held on June 10, 2021 on the second call
Regulatory News:
THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker:
ALTER), a company specializing in in vitro diagnostics and
theranostics, announces that its Shareholders’ Meeting has adopted
all of the ordinary resolutions, and that an Extraordinary
Shareholders’ Meeting will be held on June 10, 2021 on the second
call.
The Company’s shareholders approved all resolutions tabled
within the framework of the Ordinary Shareholders’ Meeting. These
resolutions can be consulted in the presentation of the General
Meeting of May 6, 2021 available on Theradiag's website in the
General Meeting section. Theradiag would like to thank its
shareholders for their commitment and support.
Given the ongoing restrictions associated with the COVID-19
pandemic, Theradiag’s Shareholders’ Meeting was held behind closed
doors and broadcast live online. You can find the broadcast in the
General Meeting section of the Company’s website.
Quorum was not met (22.86%), meaning that the extraordinary
resolutions could not be debated. An Extraordinary General Meeting
on the second call will therefore be held from 2 pm CEST on June
10, 2021, also behind closed doors, with the same agenda. A notice
of second call will be published on May 17, 2021 in the BALO French
legal announcements journal and JAL legal notices journal.
Any shareholders in the Company who have not voted thus far are
invited to vote exclusively remotely before the Shareholders’
Meeting on the second call. You may:
- vote online via the VOTACCESS platform. This platform
will be open for the second call from May 17, 2021 until 3 pm
CEST on June 9, 2021.
- vote by proxy or by post, in accordance with the terms and
conditions specified in the notice of second call. These votes will
be taken into account up until and including June 7, 2021.
The votes of shareholders who voted remotely for the first
Shareholders’ Meeting will remain valid and be counted for the
Shareholders’ Meeting on the second call.
All the preparatory documents remain available in the General
Meeting section of the Company’s website. If you have any questions
about the voting arrangements, please contact the Investor
Relations team by email at theradiag@newcap.eu.
As it will not be possible to ask questions during the
Shareholders’ Meeting, Theradiag recommends that shareholders who
wish to do so send in their written questions, together with a
certificate of account registration, from the Meeting’s second
call, preferably by email (AG@theradiag.com). These questions will be taken
into account upon receipt no later than the second working day
preceding the date of the Meeting, i.e. Tuesday June 8, 2021.
Lastly, shareholders will be able to follow the Shareholders’
Meeting on the second call from 2 pm CEST on June 10 by conference
call via the following link:
https://us02web.zoom.us/webinar/register/WN_fIC-I7GzTSeRb4BeSupaMQ
(please register prior to the date of the Meeting). The conference
call will be available afterwards in the General Meetings section
of the Company’s website.
***
Financial calendar:
- Extraordinary Shareholders’ Meeting on second call, on
Thursday June 10, 2021 - H1 2021 revenue, on Monday July 19,
2021 - H1 2021 results, on Monday September 20, 2021
About Theradiag
Theradiag is the market leader in biotherapy monitoring.
Capitalizing on its expertise in the diagnostics market, the
Company has been developing, manufacturing and marketing innovative
in vitro diagnostic (IVD) tests for over 30 years.
Theradiag pioneered “theranostics” testing (combining therapy
with diagnosis), which measures the efficacy of biotherapy in the
treatment of chronic inflammatory diseases. Going beyond mere
diagnosis, Theranostics aims to help clinicians set up “customized
treatment” for each patient. This method favors the
individualization of treatment, evaluation of its efficacy and the
prevention of drug resistance. In response to this challenge,
Theradiag develops and markets the CE-marked TRACKER® range, a
comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has
operations in over 70 countries and employs over 60 people. In
2020, the Company posted revenue of €10.4 million. The Theradiag
share is listed on Euronext Growth Paris (ISIN: FR0004197747) and
is eligible for the French PEA-PME personal equity plan.
For more information about Theradiag, please visit our website:
www.theradiag.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210510005660/en/
Theradiag Bertrand de Castelnau CEO/Managing
Director Tel.: +33 (0)1 64 62 10 12 contact@theradiag.com
NewCap Financial Communications & Investor Relations
Pierre Laurent Quentin Massé Tel.: +33 (0)1 44 71 94
94 theradiag@newcap.eu
NewCap Media Relations Nicolas Mérigeau Tel.: +33
(0)1 44 71 94 98 nmerigeau@newcap.fr
Grafico Azioni Theradiag (EU:ALTER)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Theradiag (EU:ALTER)
Storico
Da Apr 2023 a Apr 2024